| 2026-09-24 |
Alzinova AB |
Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference alzinova.com ↗ |
| 2026-09-10 |
Alzinova AB |
Alzinova initiates operational start-up of global Phase 2 study with ALZ-101 alzinova.com ↗ |
| 2026-05-20 |
Alzinova AB |
Alzinova’s clinical results with ALZ-101 now published in Alzheimer’s Research & Therapy alzinova.com ↗ |
| 2026-05-12 |
Alzinova AB |
Interview with Dr. Marwan Sabbagh – why ALZ-101 represents a next-generation approach in Alzheimer’s Disease alzinova.com ↗ |
| 2026-05-11 |
Alzinova AB |
Alzinova’s clinical results with ALZ-101 to be published in scientific journal alzinova.com ↗ |
| 2025-11-11 |
Alzinova AB |
Alzinova to participate at CTAD 2025 with two presentations on ALZ-101 alzinova.com ↗ |
| 2025-10-04 |
Alzinova AB |
Alzinova Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer’s Disease alzinova.com ↗ |
| 2025-09-04 |
Alzinova AB |
Alzinova Receives FDA (IND) Approval for Phase II Study of ALZ-101 in Alzheimer’s Disease alzinova.com ↗ |
| 2025-06-19 |
Alzinova AB |
Alzinova’s ALZ-101 vaccine shows new promising results in normalizing protective antibody levels in Alzheimer’s disease patients alzinova.com ↗ |
| 2025-06-17 |
Alzinova AB |
Alzinova selects Worldwide Clinical Trials as CRO partner for Phase 2 study of ALZ-101 alzinova.com ↗ |
| 2025-06-12 |
Alzinova AB |
ALZ-101 immunization generates sustained plasma IgG and predictable CSF antibody levels against neurotoxic oligomers alzinova.com ↗ |
| 2025-06-02 |
Alzinova AB |
Alzinova engages in discussions with potential partners and explores development strategies for ALZ-101 at BIO International Convention 2025 in Boston alzinova.com ↗ |
| 2025-04-24 |
Alzinova AB |
Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial alzinova.com ↗ |
| 2025-03-27 |
Alzinova AB |
Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease alzinova.com ↗ |
| 2025-02-19 |
Alzinova AB |
A higher dose of ALZ-101 also shows good safety and tolerability alzinova.com ↗ |
| 2024-12-09 |
Alzinova AB |
Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease alzinova.com ↗ |
| 2024-11-11 |
Alzinova AB |
Patient data from the extension part of Alzinova's phase 1b study with ALZ-101 is being processed alzinova.com ↗ |
| 2024-09-19 |
Alzinova AB |
Alzinova: First participant has successfully completed the entire phase 1b study with ALZ-101 alzinova.com ↗ |
| 2024-05-21 |
Alzinova AB |
Alzinova: First patient dosed with a higher dose of ALZ-101 in the phase 1b study alzinova.com ↗ |
| 2024-01-30 |
Alzinova AB |
Alzinova: Primary analysis confirms positive phase 1b results with ALZ-101 against Alzheimer’s alzinova.com ↗ |
| 2023-11-29 |
Alzinova AB |
Alzinova announces positive phase 1b results with the vaccine candidate ALZ-101 against Alzheimer's disease alzinova.com ↗ |
| 2023-05-29 |
Alzinova AB |
First patient dosed in the extension part of the phase 1b study with ALZ-101 alzinova.com ↗ |
| 2023-05-04 |
Alzinova AB |
Alzinova: New positive interim data from ongoing phase 1b study with vaccine candidate ALZ-101 – Initiates extension of the study alzinova.com ↗ |
| 2023-04-05 |
Alzinova AB |
Interest from potential partners and positive response to ALZ-101 at the AD/PD™ conference alzinova.com ↗ |
| 2023-03-29 |
Alzinova AB |
Alzinova presents promising data for the ALZ-101 vaccine at the international Alzheimer conference AD/PD™ alzinova.com ↗ |
| 2023-03-16 |
Alzinova AB |
Alzinova: New positive safety review of the Phase 1b study for the ALZ-101 vaccine alzinova.com ↗ |
| 2022-12-12 |
Alzinova AB |
Alzinova announces new positive safety review and interim data from ongoing phase 1b study with vaccine candidate ALZ-101 alzinova.com ↗ |
| 2022-08-03 |
Alzinova AB |
Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ALZ-101 alzinova.com ↗ |
| 2022-07-05 |
Alzinova AB |
Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2 alzinova.com ↗ |
| 2022-03-30 |
Alzinova AB |
Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements alzinova.com ↗ |
| 2021-10-29 |
Alzinova AB |
First patient recruited into Alzinova’s phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer’s disease alzinova.com ↗ |
| 2021-09-30 |
Alzinova AB |
Alzinova receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer’s disease alzinova.com ↗ |
| 2021-04-21 |
Alzinova AB |
Status update regarding application to start clinical study with ALZ-101 alzinova.com ↗ |
| 2021-01-08 |
Alzinova AB |
Drug substance for the ALZ-101 vaccine is now produced – meets the requirements of the upcoming clinical Phase 1b study alzinova.com ↗ |
| 2020-11-04 |
Alzinova AB |
Alzinova AB announces the study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 at a scientific congress. alzinova.com ↗ |
| 2020-10-15 |
Alzinova AB |
Alzinova AB (publ) has received positive feedback from the Finnish Medicines Agency Fimea in view of the upcoming clinical trial application for the ALZ-101 Alzheimer's disease vaccine alzinova.com ↗ |
| 2020-09-18 |
Alzinova AB |
Alzinova carries out a 95 percent guaranteed rights issue of units of approximately SEK 50 million to finance the clinical development of ALZ-101 alzinova.com ↗ |
|